| Features: |
| Treatment of disease with radiation, especially by selective irradiation with x-rays or other ionizing radiation and by ingestion of radioisotopes. Radiosensitizer Atorvaqone, (mitochondria inhibitor) decrease O2 consumption making more O2 available as a radiosensitizer. |
| Source: |
| Type: |
| TrxR1 or TXNRD1 (Thioredoxin Reductase 1) Redox Control, Stress Tolerance, and Therapy Resistance • Many studies have found that an elevated expression of TrxR1 in breast tumors, NSCLC, HCC correlates with increased tumor aggressiveness and a poorer prognosis. -TrxR1 expression was elevated by >50 fold in FaDu and HeLa cells, and by >20 fold in SCC-1 compared to either MSK-Leuk1 or keratinocytes.
High TXNRD1 expression often associates with:
-Advanced stage
-Therapy resistance
-Reduced survival
TrxR1 Inhibition
-Collapses redox control
-Causes rapid ROS accumulation
-Triggers apoptosis, especially in high-stress tumors
|
| 2902- | HNK, | Rad, | Honokiol Mitigates Ionizing Radiation-Induced Injury by Maintaining the Redox Balance of the TrxR/Trx System |
| - | in-vitro, | Nor, | BEAS-2B |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:201 Target#:1207 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid